516481-35-9Relevant academic research and scientific papers
Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles
Arienti, Kristen L.,Brunmark, Anders,Axe, Frank U.,McClure, Kelly,Lee, Alice,Blevitt, Jon,Neff, Danielle K.,Huang, Liming,Crawford, Shelby,Pandit, Chennagiri R.,Karlsson, Lars,Breitenbucher, J. Guy
, p. 1873 - 1885 (2007/10/03)
The discovery of a series of novel, potent, and highly selective inhibitors of the DNA damage control kinase chk2 is disclosed. Here we report the first SAR study around inhibitors of this kinase. High-throughput screening of purified human chk2 led to the identification of a novel series of 2-arylbenzimidazole inhibitors of the kinase. Optimization was facilitated using homology models of chk2 and docking of inhibitors, leading to the highly potent 2-arylbenz-imidazole 2h (IC50 15 nM). Compound 2h is an ATP-competitive inhibitor of chk2 that dose dependency protects human CD4 + and CD8+ T-cells from apoptosis due to ionizing radiation. This work suggests that a selective small molecule inhibitor of chk2 could be a useful adjuvant to radiotherapy, increasing the therapeutic window of such treatment.
Substituted benzimidazoles and imidazo-[4,5]-pyridines
-
, (2008/06/13)
2-Aryl substituted benzimidazoles and imidazo[4,5]pyridines are disclosed as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.
